Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer
July 20 2021 - 7:00AM
(NASDAQ: ENOB) -- Enochian BioSciences, Inc., a company focused on
gene-modified cellular and immune therapies in infectious diseases
and cancer, today announced that Honorable Mark Dybul, M.D. has
been named as Chief Executive Officer (CEO).
Dr. Dybul, who has served as Executive
Vice-Chair of the Board of Enochian BioSciences since January 2019,
is a globally recognized leader in pandemics. He was a principal
architect and ultimately the head of the U.S. President’s Emergency
Plan for AIDS Relief (PEPFAR), the largest international health
initiative in history dedicated to a single disease, that achieved
historic prevention, care and treatment goals on time and on
budget. During his tenure, the program grew from approximately $500
million to $6.5 billion annually. Dr. Dybul went on to transform
the Global Fund to Fight AIDS, Tuberculosis and Malaria and, during
Dr. Dybul’s four-year tenure, both President Barack Obama and Prime
Minister Justin Trudeau hosted funding rounds that raised $25
billion for the Global Fund.
Dr. Dybul has been deeply involved in the fight
against COVID-19. He was the only American appointed to the
15-member Independent Panel for Pandemic Preparedness and Response,
mandated by the World Health Assembly and co-chaired by former
Liberian President Ellen Johnson Sirleaf and former New Zealand
Prime Minister Helen Clark. Dr. Dybul also was a member of the High
Level Scientific Advisory Group for the G20’s Global Health Summit
focused on COVID-19.
Under the mentorship of Dr. Anthony Fauci, Dr.
Dybul began his career in public health as a researcher at the
National Institute of Allergy and Infectious Diseases, ultimately
leading a section of Dr. Fauci’s lab and serving as the Assistant
Director for Medical Affairs.
“It is a great privilege to have one of the
world’s preeminent public health experts assume the role of CEO of
Enochian BioSciences,” said Enochian BioSciences’ Chair of the
Board René Sindlev. “Mark’s deep expertise in science, combined
with his long experience managing research programs and advising on
strategy, brings key and difficult-to-find competencies to Enochian
BioSciences. Under Mark’s leadership, we are excited to see the
organization rapidly advance toward its goal of developing cures
for HBV, HIV and potentially, to address inhaled pan-coronavirus
and pan-influenza treatment and prevention.”
Gregg Alton, Enochian BioSciences’ Board
Director and former interim CEO, said, “I have known Mark since he
worked closely with Tony Fauci, when I was General Counsel at
Gilead Sciences. I watched him lead what was effectively a start-up
in the U.S. Government, PEPFAR, and make it one of the most
successful public health programs in history. Mark then went on to
transform the Global Fund, a public-private partnership,
introducing business models for purchasing, supply chain, and many
others. He knows how to lead, develop strategy, maintain the teams’
focus and achieve success.”
“As a long-time researcher, clinician, and
leader of large global diseases programs, I am very honored to
transition from my current role of Executive Vice-Chair to
full-time CEO of Enochian BioSciences,” said Dr. Dybul. “Based in
elegantly brilliant science, we have made significant progress in
the past 18 months building a deep and wide pipeline with platforms
that address major killers including cancer and infectious
diseases. The recent acceleration of potential cures for Hepatitis
B, HIV and potential inhaled pan-coronavirus, including the cause
of COVID-19, and pan-influenza treatment and prevention — makes it
an extremely exciting time to become the CEO of Enochian
BioSciences.”
About Enochian BioSciences,
Inc.Enochian BioSciences, Inc. is a biopharmaceutical
company focused on developing innovative platforms for
gene-modified cellular and immune therapies to potentially cure and
treat deadly diseases. The company’s gene-modified cell and immune
therapy platforms can potentially be applied to multiple
indications, including HIV/AIDS, Hepatitis B, all Corona and
Influenza viruses, and Oncology. For more information, please visit
Enochianbio.com.
Forward-Looking
StatementsStatements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are
forward-looking statements, which can be identified by the use of
forward-looking terminology such as “believes,” “plans,” “expects,”
“aims,” “intends,” “potential,” or similar expressions. Actual
events or results may differ materially from those projected in any
of such statements due to various uncertainties, including those
discussed under the heading "Risk Factors" and elsewhere in
Enochian BioSciences’ most recent Annual Report on Form 10-K filed
with the SEC. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, and Enochian BioSciences
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof.
Contact: ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Sep 2023 to Sep 2024